Drug intelligence / Profile preview

heparin + piperacillin + tazobactam

Development stage
Unknown
Lead developer
Bristol Myers Squibb
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous
01

Overview

This is a combination of three drugs:

  • Heparin is an anticoagulant that works by potentiate the activity of antithrombin III, thereby inhibiting thrombin and factor Xa, leading to prevention of blood clot formation.
  • Piperacillin is a broad-spectrum penicillin-class antibacterial agent that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
  • Tazobactam is a beta-lactamase inhibitor that protects piperacillin from enzymatic degradation by beta-lactamase-producing bacteria, thereby extending its antibacterial spectrum.

The combination of piperacillin and tazobactam (often marketed as Zosyn) is used for the treatment of various serious infections including intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections, and community-acquired pneumonia. Heparin may be co-administered in clinical settings where both infection control and anticoagulation are required; however, this specific triple combination does not have a unique brand or product name. Coadministration requires monitoring due to potential interactions affecting coagulation parameters.

02

Targets

Beyond the preview

Go deeper on heparin + piperacillin + tazobactam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on heparin + piperacillin + tazobactam.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call